Skip to content
Study details
Enrolling now

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

GlaxoSmithKline
NCT IDNCT05757102ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

292

Study length

about 3.7 years

Ages

12–17

Locations

28 sites in AL, AZ, CA +12

About this study

Researchers are testing whether a new asthma treatment called FF/UMEC/VI is better than an existing treatment called FF/VI for children aged 12 to 17 with asthma. The trial will last for about 1361 days and involve around 292 participants.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take FF/UMEC/VI
  • 2.Take FF/VI
  • 3.Use ELLIPTA
PhasePhase 3
Primary goalChange from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low6%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24

Secondary: Change from Baseline in Asthma Control Questionnaire (5 items) (ACQ-5) (Scores on a scale), Change from Baseline in Asthma Control Questionnaire (6 items) (ACQ-6) (Scores on a scale), Change from Baseline in Asthma Control Questionnaire (7 items) (ACQ-7) (Scores on a scale), Number of Participants with a clinically important change from baseline in ACQ-5 Score, Number of Participants with a clinically important change from baseline in ACQ-6 Score, Number of Participants with a clinically important change from baseline in ACQ-7 Score

Body systems

Respiratory